Heart International. 2023;17(1):60–2 DOI: https://doi.org/10.17925/HI.2023.17.1.60
Bradycardia, renal failure, atrioventricular nodal blockade, shock and hyperkalemia (BRASH) syndrome is a rare, often unrecognized but potentially life-threatening clinical entity that is characterized by the pentad of symptoms after which it is named. BRASH syndrome is seen most commonly in the setting of atrioventricular nodal-blocking medications such as beta-blockers and calcium channel blockers.1,2 The synergistic interplay of […]